Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

AgPlenus and Corteva identify new herbicide molecule

EditorAhmed Abdulazez Abdulkadir
Published 2024-03-06, 08:26 a/m
© Reuters.

REHOVOT, Israel - AgPlenus Ltd., a subsidiary of Evogene Ltd . (NASDAQ:EVGN) (TASE:EVGN), announced a significant advancement in its collaboration with Corteva Agriscience (NYSE:NYSE:CTVA). The companies have successfully identified a new family of molecules, APCO-12, with a novel Mode of Action (MoA) for herbicide development.

The herbicide market is projected to reach $42.81 billion in 2024. The agricultural sector has been challenged by weed resistance due to the limited introduction of new MoAs over the past thirty years. The collaboration, which started in 2020, combines Corteva's product discovery expertise with AgPlenus's computational platform to address this issue.

Today, the partnership revealed the discovery of a potential new class of herbicidal molecules. The next phase will optimize these molecules for commercial use, leveraging AgPlenus's computational technology, powered by Evogene's ChemPass AI tech engine, and Corteva's R&D capabilities.

Vid Hegde, VP of Crop Protection Discovery (NASDAQ:WBD) and Development at Corteva, emphasized the critical need for new technologies to combat weed resistance. He acknowledged the collaboration's acceleration in identifying a new herbicide chemistry targeting a novel MoA.

Dr. Dan Gelvan, CEO of AgPlenus, expressed excitement over the milestone and the synergy between the teams. He reiterated AgPlenus's commitment to sustainable agriculture and the goal of providing innovative herbicide solutions to farmers globally.

AgPlenus is a technology platform company focused on the discovery of sustainable crop protection products to ensure food security. The company uses a target-based approach to minimize risks and enhance effectiveness in developing novel crop protection products.

Evogene is a computational biology company that uses Big Data and AI to revolutionize life-science-based product development, aiming to improve success rates while reducing time and cost. It operates through subsidiaries and strategic partnerships across various sectors, including human therapeutics, agriculture, and biofuels.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This news article is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.